You are a bit wrong, the 2 current AML trials are NK-cell based...

You are a bit wrong, the 2 current AML trials are NK-cell based ALLOGENEIC CAR-Ts. Unfortunately Dr Bec has put the focus away from those but more in regards to funding as the trial based at MD Anderson is shared cost and the other one at Ohio Uni is free apart of supplying the cells.

The CHM CORE NK platform is a Clinically validated, Off the shelf, Robust and Enhanced Natural
Killer (NK) cell platform. The platform uses a novel, proprietary genetically-modified feeder cell
line to activate and expand universal off-the-shelf allogeneic NK cell products derived from
healthy donors. The expanded CORE-NK cells exhibit enhanced cytotoxicity, metabolism, and
expression of activating receptors compared to fresh, activated NK cells. From the CORE-NK
platform, Chimeric is developing next generation NK and CAR NK assets with plans for phase 1
clinical trials in solid tumours and blood cancers.

Her focus is on CDH17 as one of the few first mono CAR-Ts to directly target solid gastric cancers. According to Dr Bec both, the GBM and the CDH17 CAR-Ts have currently no technical / biological option to be done allogeneically.

The GBM CLTX CAR-T's formula has seen a better than gold standard results but the ph 1b roll out across the USA and AUS has stalled due to lack of specialists. Currently paused or just continued at City of Hope and MD Anderson.

The problem for CHM is that the NK platform performs well but not well enough to be at the forefront of about 300 trials targeting CD19 and that the front runners GBM performs well and CDH17 could perform well but aren't seen by the market as having a realistically positive commercial outcome at this stage.

Hence, funding problems. All depends on Dr Bec's abilities and connections to get the funds needed. Only she can achieve the " Impossible " to refloat CHM. The other board members proved their incapabilities more than once last year. The only board decision done right so far was hiring Dr Bec.

Huge risk and reward scenario.